OncoMatch/Clinical Trials/NCT06053658
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Is NCT06053658 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tivozanib and Nivolumab for renal cell carcinoma.
Treatment: Tivozanib · Nivolumab — To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: VEGFR inhibitor (tivozanib)
Prior tivozanib therapy
Cannot have received: anti-PD-1 therapy (nivolumab)
Prior nivolumab therapy
Lab requirements
Blood counts
absolute neutrophil count ≥1,000/mcL; platelets ≥100,000/mcL
Kidney function
creatinine ≤1.5 × institutional ULN; eGFR ≥30 ml/min
Liver function
total bilirubin ≤ institutional upper limit of normal (ULN); AST ≤3 × institutional ULN; ALT ≤3 × institutional ULN
Cardiac function
NYHA Functional Classification class 2B or better
Patients must have adequate organ and marrow function as defined below: 1. absolute neutrophil count ≥1,000/mcL 2. platelets ≥100,000/mcL 3. total bilirubin ≤ institutional upper limit of normal (ULN) 4. AST ≤3 × institutional ULN 5. (ALT) ≤3 × institutional ULN 6. creatinine ≤1.5 × institutional ULN 7. eGFR ≥30 ml/min ...patients should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
- University of Michigan · Ann Arbor, Michigan
- UT Southwestern Medical Center · Dallas, Texas
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify